Dear Veterinarian Letter regarding adverse events associated with extra-label use of fenbendazole in dogs (2024)

Government Record · U.S. Food and Drug Administration, Center for Veterinary Medicine · April 8, 2024

U.S. Food et al., 2024-04-08: FDA veterinary safety communication reporting twelve canine cases of bone marrow hypoplasia or pancytopenia after fenbendazole given longer than the labelled three days. Treatment length in the reported cases ranged from 5 to 14 days.

As of October 20, 2023, FDA has received 12 reports of bone marrow hypoplasia or pancytopenia in dogs being treated with fenbendazole in this extra-label manner.

U.S. Food et al., 2024-04-08: FDA veterinary safety communication reporting twelve canine cases of bone marrow hypoplasia or pancytopenia after fenbendazole given longer than the labelled three days. Treatment length in the reported cases ranged from 5 to 14 days. Regulatory adverse-event summary (not a controlled study); N=12 dogs plus "a few reports" in other species; United States; doses not stated per case, but all exceeded the labelled 50 mg/kg for 3 days, with treatment length 5-14 days; indications included Giardia, flukes, coccidia, lungworms and skin parasites. Funder: FDA. Comparator: none. The page carries no day-level date; the letter's own cut-off is 20 October 2023 and it was issued in October 2023 (access date 2026-11-20; page undated beyond that). This is animal data and does not establish human risk, but it is the regulator's own bone-marrow finding for this drug. Also filed as FBE-55 (claims C2, C6). Study type: regulatory record.